New cocktail aims to tackle hodgkin lymphoma without prior treatment
NCT ID NCT05922904
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This phase 2 trial tests a combination of two targeted drugs (brentuximab vedotin and pembrolizumab) plus standard chemotherapy (doxorubicin and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach is safe and effective. Participants have stage II bulky disease or stage III/IV classic Hodgkin lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin, pembrolizumab, doxorubicin, dacarbazine
What this could lead to
If successful, this could offer a more effective first-line treatment for advanced Hodgkin lymphoma, potentially reducing the need for more toxic therapies.
What could go wrong
This is a small, early-phase trial (25 people) focused on safety and response. Results may not apply to all patients, and side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.